Prosecution Insights
Prosecution Insights
6 pending office actions • 3 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (50%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 2 | 79.3% | +15.8% |
| PAK, MICHAEL D | 1 | 58.5% | +30.3% |
| KIM, YUNSOO | 1 | 65.8% | +34.8% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.0% |
| LI, RUIXIANG | 1 | 59.4% | +19.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17938421 | TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF | LI, RUIXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18176155 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS | KIM, YUNSOO | 121d overdue |
| 18451632 | Methods and Compositions for Treating Cancer | PAK, MICHAEL D | 10d overdue |
| 18168192 | COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | 33d |
| 18776612 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | — |
| 18777239 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | — |
| 17938421 | TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF | LI, RUIXIANG | — |
| Art Unit | Apps |
|---|---|
| 1674 | 2 |
| 1641 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18776612 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | — | §112Other | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18777239 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | — | §112DP | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18451632 | Methods and Compositions for Treating Cancer | PAK, MICHAEL D | 1674 | §112 | Non-Final OA | 10d overdue | Pending | Aug 17, 2023 |
| 18176155 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS | KIM, YUNSOO | 1641 | §112 | Final Rejection | 121d overdue | Pending | Feb 28, 2023 |
| 18168192 | COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | 1644 | Other | Non-Final OA | 33d | Pending | Feb 13, 2023 |
| 17938421 | TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF | LI, RUIXIANG | 1674 | §102§112 | Non-Final OA | — | Pending | Oct 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial